The latest generation of ProFound AI Risk offers the ability to calculate a short-term risk estimation for 3D mammography, with greater accuracy compared to both the previous version of the risk software based on 2D mammography and traditionally used risk models. Expanded features include the ability to calculate short-term (one-, two- or three-year) absolute risk based on either 2D or 3D mammography images. Specifically designed to factor in racial and ethnic backgrounds, ProFound AI Risk also factors in clinically relevant global screening guidelines and more than 15 country incidence and mortality reference tables, for alignment with that country's general population.

The latest version of iCAD's PowerLook Density Assessment software enables clinicians to automate breast density assessment accurately and reliably, removing the challenges of subjectivity. It identifies the patient's anatomy, segments the breast, then measures adipose and fibroglandular tissue and its dispersion to determine the density category in alignment with BI-RADS® 5th Edition lexicon. Its consistent scores bring confident density assessment and standardized stratification in density-based breast cancer screening and reporting.

About iCAD, Inc.
Headquartered in Nashua, New Hampshire, USA, iCAD® is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.


About Arterys
Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions. For more information on Arterys, please visit www.arterys.com.

Back to HCB News

Women's Health Homepage